Evidence map›Paper›PMID 42450320›Full record

ArticleInternational journal of molecular sciences2026

FAK and Pyk2: Paralogous Kinases with Opposing Roles in Vasculogenic Mimicry in Triple-Negative Breast Cancer.

Shilpa Madhavan-Kadali, Tal Sneh, Naamah Bloch, Joseph D Rosenblatt, Abraham O Samson, Hava Gil-Henn

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shilpa Madhavan-KadaliAzrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.ORCID 0000-0002-3693-6279
Tal SnehAzrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.
Naamah BlochAzrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.ORCID 0009-0005-7886-4049
Joseph D RosenblattDepartment of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Centre, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Abraham O SamsonAzrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.
Hava Gil-HennAzrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.

Funding

Florida Department of Health 09BR-02Israel Cancer Association 20210071Israel Cancer Research Fund 20-101-PGIsrael Science Foundation 2142/21
6 · The paper itself

Abstract

Vasculogenic mimicry (VM) is a non-endothelial mode of tumor vascularization in which aggressive cancer cells form vessel-like networks that support microcirculation, metastasis, and resistance to anti-angiogenic therapies. VM is particularly prominent in triple-negative breast cancer (TNBC), but its molecular regulators remain incompletely understood. Focal adhesion kinase (FAK) and its paralog, proline-rich tyrosine kinase 2 (Pyk2), are closely related non-receptor tyrosine kinases implicated in epithelial-to-mesenchymal transition (EMT), invasion, and metastasis in TNBC. However, their roles in VM have not been defined. Here we perform transcriptomic analysis of FAK and Pyk2 clinical expression patterns using TNMplot V2, DepMap, and patient cohort datasets to systematically dissect the distinct contributions of FAK and Pyk2 to VM in TNBC. Our in vitro tube formation assay shows that in TNBC cells, knockdown of FAK, but not Pyk2, results in failure to form robust 3D vessel-like networks in Matrigel. Similarly, overexpression of Pyk2, but not FAK, in TNBC cells results in poor vessel-like network formation. Consistent with these findings, analysis of two independent patient cohorts (TCGA-BRCA and METABRIC) revealed selective upregulation of FAK in TNBC, while Pyk2 was inversely associated with vasculogenic-mimicry-associated gene expression, supporting the opposing roles of the two kinases in patient tumors. Taken together, these findings establish that FAK and Pyk2 govern VM through non-redundant, kinase-specific, and functionally opposed mechanisms: FAK acting as a positive regulator of VM, and Pyk2 as a context dependent suppressor of VM at elevated levels. These results nominate FAK as a candidate target for suppressing VM-driven tumor perfusion in TNBC and suggest that dual FAK/Pyk2 inhibition warrants caution hypotheses that remain to be tested pharmacologically.

Indexed as

Focal Adhesion Kinase 1Focal Adhesion Kinase 2Neovascularization, PathologicTriple Negative Breast NeoplasmsCell Line, TumorEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansFocal Adhesion Kinase 1Focal Adhesion Kinase 2PTK2B protein, humanPTK2 protein, humancell migrationFAKfocal adhesion kinasenon-receptor tyrosine kinasesPTK2PTK2BPyk2triple negative breast cancertumor vascularizationvasculogenic mimicry

Identifiers

PMID42450320
PMCPMC13362414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.